



Supplementary Figure 1








IL-6 production after P3C stimulation



p=0.068

p=0.083

p=0.058



a: Study schedule of the Tribute study. Blood was collected and PBMCs were isolated at three time points during the BCG induction cycle: pre-BCG1, BCG2 and BCG6; and two time points during each subsequent BCG maintenance

cycle: pre-BCG1, BCG2 and BCG5; and two time points during each subsequent BCG maintenance cycle: pre-BCG7, BCG9, pre-BCG10, BCG12, pre-BCG13 and BCG15. Some patients discontinued with BCG (see Supplementary Table 2). Light blue arrow indicates pre-BCG1 time point which is used to calculate fold change in cytokine production. Purple arrows indicate important time points for TI, as patients did not receive BCG for weeks to months and thus represent the best 'innate immune memory' time points.

b: IL-6 production by PBMCs after 24 hour stimulation with LPS at 8 time points during BCG therapy compared to pre-BCG1.

c: IL-6 production by PBMCs after 24 hour stimulation with P3C at 8 time points during BCG therapy compared to

d: IL-1Ra production by PBMCs after 24 hour stimulation with LPS at 8 time points during BCG therapy compared to pre-BCG1.

e: IL-1Ra production by PBMCs after 24 hour stimulation with P3C at 8 time points during BCG therapy compared to pre-BCG1.

Individual patient fold change values are displayed as grey dots. Group values for each time point are displayed as median ± range in fold change compared to pre-BCG1. Two tailed matched-pair Wilcoxon signed-rank test was used to determine statistical significance in cytokine production between time points. Statistical significance was accepted at p<0.05 and indicated as follows: * p<0.05 and **p<0.01. **** p≤0.001 ***** p≤0.0001. Number of data points per time point for b: pre-BCG1: 17, BCG2: 17, BCG6: 16, pre-BCG7: 13, BCG9: 13, pre-BCG1: 17, BCG2: 17, BCG6: 16,

pre-BCG7: 14, BCG9: 13, pre-BCG10: 8, BCG12: 7, pre-BCG13: 3, BCG15: 3.